Etranacogene dezaparvovec. infusion bulk supplier for pharma manufacturers

Etranacogene Dezaparvovec. Infusion Cells/kg patient Suppliers & Bulk Manufacturers

Available Forms: Intravenous infusion

Available Strengths: Cells/kg patient

Reference Brands: Hemgenix (US & EU)

Etranacogene dezaparvovec (AMCECVIT) is a gene therapy that delivers a functional FIX gene to treat hemophilia B. It provides sustained, long-term factor IX production, reducing bleeding episodes, decreasing need for regular infusions, and improving quality of life with a one-time administration in suitable patients.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Etranacogene Dezaparvovec. Infusion? List it or send an offer →

Product Description:

Etranacogene dezaparvovec (AMECVIT) is regulated in the EU and US, supported by dossiers demonstrating safety, efficacy, and manufacturing quality in compliance with GMP and MDR standards. In the US, FDA approval involved extensive clinical validation, safety assessments, and comparability data. In the EU, CE marking certifies conformity with MDR regulations. These gene therapies undergo validation, stability testing, and audits, supported by comprehensive documentation including safety profiles, clinical trial results, and manufacturing practices. Ensuring regulatory compliance guarantees access to innovative gene therapies supporting hemophilia B management worldwide, promoting effective treatment and improved patient outcomes.

Etranacogene Dezaparvovec. Infusion — third party manufacturing & bulk supply

Etranacogene Dezaparvovec. Infusion Cells/kg patient is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Etranacogene Dezaparvovec. Infusion is supplied as Intravenous infusion — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Etranacogene Dezaparvovec. Infusion listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Etranacogene Dezaparvovec. Infusion →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Etranacogene dezaparvovec. infusion is listed as Intravenous infusion in Cells/kg patient. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Etranacogene dezaparvovec. infusion is referenced against Hemgenix (US & EU). Reference brands are shown for identification only and remain the property of their respective trademark owners.